H1.co alternative · for precision-oncology biotech medical affairs
H1 alternative for precision-oncology medical affairs: variant-aware KOL ranking
UNMIRI · See Literature Intelligence
H1's HCP Universe is a strong all-therapeutic-area KOL platform. Publications, trials, conference activity, $73B in payments data, social/digital footprint — the breadth is real. For biopharma running diverse therapeutic-area portfolios, H1 has the coverage.
UNMIRI Engine 3 is built for the slice H1 can't economically deepen: variant-aware KOL ranking for precision-oncology medical affairs.KOLs publishing on EGFR L858R are different from KOLs publishing on EGFR exon 20 insertions, and the medical affairs team launching an exon-20-insertion drug needs the second group, not the first. H1 can't do this without bolting on a genomic ontology they don't own. UNMIRI joins literature signal to the variant graph from Engines 1 and 2, so the KOL ranking is biomarker-conditioned by design.
At a glance
| Dimension | H1.co | UNMIRI |
|---|---|---|
| Scope | All therapy areas — oncology, rare disease, cardiology, neuro, etc. | Oncology-only, biomarker-stratified |
| KOL ranking signal | Aggregate publication volume, trial activity, payments, social engagement | Variant-conditioned: ranks KOLs by recent publications on a specific gene + variant pair |
| Buyer | Mid-to-large biopharma medical affairs, clinical operations, commercial analytics | 50-500 employee oncology biotech medical affairs |
| Pricing | Mid-five to low-seven figures annually, multi-year enterprise contracts | $99/mo individual, $499/mo team, $25-75K enterprise SaaS |
| Deployment time | Enterprise procurement: months to onboarding | Self-serve PLG: 14-day trial, no credit card, deployable in days |
| Output formats | H1 UI, AI-Powered Interactions for pre-call planning, Salesforce/Veeva integrations | Daily/weekly digest, KOL profiles, competitive landscape PDF, watchlist alerts, FHIR / API |
Variant-conditioned ranking is the whole point
Take a concrete example: a medical affairs team launching a KRAS G12C inhibitor in NSCLC needs to know which oncologists are publishing on G12C, not which oncologists are publishing on lung cancer generally. H1 ranks the latter. UNMIRI ranks the former because the literature signal is joined to UNMIRI's variant graph — the same Neo4j knowledge graph that powers Engines 1 and 2.
The other H1 wedge is buying motion. H1 is enterprise sales, contract negotiation, integration with Veeva or Salesforce. UNMIRI Engine 3 is PLG: trial, decide, expand. For a biotech that doesn't have enterprise procurement bandwidth and doesn't want to wait two quarters, that's the deciding factor.
When H1.co is the right pick
- You're running multi-therapeutic-area medical affairs and need one platform across oncology + rare disease + cardiology + neuro.
- You're already on Salesforce or Veeva CRM and want native integration into your pre-call planning workflow.
- Your team is mid-to-large biopharma with enterprise-procurement budget and time for a months-long deployment.
- You need payments / engagement data depth for HCP relationship management beyond literature.
When UNMIRI is the right pick
- You're at a precision-oncology biotech (50-500 employees) where every KOL recommendation needs to be specific to your drug's biomarker.
- Your team is six to twenty MSLs, not a hundred. Enterprise procurement isn't a fit; PLG self-serve is.
- Variant-aware ranking is the actual deliverable. "Top-10 oncology KOLs by recent publications on KRAS G12C in NSCLC" is the daily query, not "top oncology KOLs."
- You want to evaluate it Tuesday, not negotiate it for two quarters.
- Your MLR review process favors deterministic-template output over multi-source aggregated scoring.
Frequently asked questions
- Does UNMIRI cover non-oncology therapeutic areas?
- No. UNMIRI is oncology-only by design. The variant graph is oncology-specific. If you need rare disease, immunology, cardiology, or neuro KOL coverage, H1 is the right tool and UNMIRI isn't in the running.
- Can we run UNMIRI alongside an existing H1 subscription?
- Yes. Many do during evaluation. There's no exclusivity. UNMIRI handles the variant-aware KOL slice; you keep H1 for everything outside oncology or for non-variant-stratified workflows.
- How does the variant-aware ranking actually work?
- The relevance score and KOL ranking incorporate variant-level signal from the Neo4j knowledge graph. When you set a watchlist with "KRAS G12C + NSCLC," the KOL feed surfaces oncologists who have authored on that specific variant + indication pair recently, ranked by publication recency, citation density, and conference activity tied to that variant — not by aggregate oncology publication volume.
- What about Salesforce / Veeva integration?
- UNMIRI Engine 3 has FHIR / API output but doesn't ship native Salesforce or Veeva CRM connectors. If those integrations are non-negotiable, H1 is the better fit today. UNMIRI is evaluating partner integrations once design-partner volume justifies the engineering.
Try the variant-aware feed
14-day trial, no credit card. Set your watchlist to your drug + biomarker + competitive set, and see how variant-conditioned ranking differs from generic KOL discovery.